How We Got Here
SLBST Pharma seeks to address the pain of endometriosis by repurposing a 60-year-old drug as the first non-hormonal, long-term treatment. The company holds issued US and European patents for the use of hydroxychloroquine (HCQ) to treat endometriosis. HCQ has an excellent safety record and is well-tolerated by the tens of millions of patients who’ve used it over the decades for lupus (SLE). Roughly one-in-ten women of childbearing age suffer from endo, representing over 20M women in the US and Europe. Two-thirds of women taking the existing hormonal treatments for endo express dissatisfaction. There is a large unmet need for an endo treatment compatible with conception and pregnancy (which HCQ is). Following a positive consultation with the FDA in early 2022, the company is preparing an IND application to begin a Phase 2b clinical trial in the spring of 2023.